Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
Effects of dietary manipulation on vascular status of patients with peripheral vascular disease.
In a one-year , double-blind clinical trial , 45 patients with peripheral vascular disease ( PVD ) were r and omly assigned to either the American Heart Association Hyperlipidemia Diet C ( n = 20 ) or a low-fat , high-fiber , complex carbohydrate diet similar to the Pritikin Maintenance Diet ( n = 25 ) . Vascular status and blood lipid levels were monitored at 0 , 2 , 4 , 6 , and 12 months . Walking distance increased significantly in both groups , with no difference between groups . No vascular parameters changed significantly , suggesting that increased walking distance was due to improved metabolic capacity of the muscle . A trend toward lower blood lipid values was observed , with no significant differences within or between groups . We conclude that while patients with PVD benefit from a program of diet and exercise , there is no apparent advantage to the more difficult complex carbohydrate diet
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .